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Summary Virtually all asthma patients use bronchodilators. Formoterol and
salbutamol have a rapid onset of bronchodilating effect, whereas salmeterol acts
slower. We studied the onset of improvement of dyspnoea sensation after inhalation
with these bronchodilators and placebo to reverse a methacholine-induced
bronchoconstriction as a model for an acute asthma attack.
Seventeen patients with asthma completed this randomised, double-blind,
crossover, double-dummy study. On 4 test days, forced expiratory volume in 1 s
(FEV1) and Borg score were recorded and patients were challenged with methacho-
line until FEV1 fell with X30% of baseline value. Thereafter, formoterol 12 mg via
Turbuhalers, salbutamol 50 mg via Turbuhalers, salmeterol 50 mg via Diskhalert, or
placebo was inhaled. FEV1 and Borg scores were assessed during the following
60min.
The first sensed improvement of Borg score was significantly (Po0:05) faster
achieved with formoterol (geometric mean (Gmean) (range) 1.5 (1–40)min) and
salbutamol 1.8 (1–10)min than with salmeterol 4.5 (1–30)min and placebo 3.4 (1–
40)min.
The Borg score returned significantly faster to the baseline value with formoterol,
salbutamol, and salmeterol (Gmean time 13.8 (1–75), 13.4 (1–60), and 18.0 (1–
75)min, respectively) than with placebo (33.6 (1–75min).
Formoterol and salbutamol act significantly faster than salmeterol in relieving
dyspnoea induced by methacholine-induced bronchoconstriction, in patients with
asthma.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Asthma is characterised by episodes of acute
bronchoconstriction which are clinically perceived
as dyspnoea.1 There is considerable evidence that
dyspnoea has a pronounced effect on a patient’s
quality of life.2 It is even postulated that dyspnoea
is the most important symptom to drive patients to
consult their general practitioner for relief of
symptoms.3
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Patients’ adherence to therapy enhances when
confidence in medication increases.4 This confi-
dence may be gained by the subjective relief of
asthma symptoms like dyspnoea. Long-acting b2-
agonists, like the long-acting formoterol and
salmeterol, are being used in the maintenance
treatment of asthma,5,6 while b2-agonists like
formoterol, salbutamol, and terbutaline with their
rapid bronchodilating effect7 are used as add-on
therapy. Though the fast effect on airway smooth
muscle relaxation is well documented, yet it is
unknown whether they provide a rapid improve-
ment in dyspnoea sensation as well. Therefore, we
investigated the onset of improvement of dyspnoea
after inhalation of formoterol, salbutamol, in
comparison with placebo in a model of an acute
asthma attack, with methacholine-induced moder-
ate to severe bronchoconstriction.
Methods
This study is a post-hoc analysis of an earlier study
which investigated the bronchodilating effect
(forced expiratory volume in 1 sFFEV1) of b2-
agonists in reversing a methacholine-induced
bronchoconstriction7 in 21 asthmatic patients.
The present report analyses the effect on Borg
scores, which was simultaneously recorded for
safety reasons.
Patients with stable asthma were invited to
participate in this randomised, double-blind, dou-
ble-dummy, placebo controlled, crossover study to
assess effect of salmeterol (Sereventt Diskhalert
50 mg, GlaxoSmithKline, Zeist, The Netherlands),
formoterol (Oxiss Turbuhalers 12 mg, AstraZeneca,
Lund, Sweden), salbutamol (50 mg Turbuhalers
AstraZeneca, Lund Sweden) or placebo (Turbuha-
lers or Diskhalert; provided by AstraZeneca, Lund
Sweden). Inclusion criteria were an age between 18
and 45 years, an FEV141.5 l and 460% predicted,
8
a provocative concentration of methacholine
causing a fall in FEV1X20% (PC20 metha-
choline)p8mgml1 and a fall in FEV1430% upon
continuation of the test, and no concomitant
diseases or conditions that might interfere with
the study. Patients had to be able to use Turbu-
halers and Diskhalert according to the instructions
of the manufacturer. The Medical Ethics Committee
of the Martini Hospital, Groningen, approved the
study. All patients gave written informed consent
before the start of the study.
The methacholine provocation test was per-
formed as described previously.7 In short, patients
inhaled increasing concentrations of methacholine
0.125–64mgml1 during a period of 2min until a
fall in FEV1 of X30% was reached. During and after
the test, the Borg score was also measured at the
same time points as when the FEV1 was assessed.
Immediately after reaching a fall in FEV1X30%,
study medication was inhaled (T¼ 0min). Subse-
quently, FEV1 and Borg score were assessed at 1, 3,
5, 10, 15, 20, 25, 30, 40, 50, and 60min.
The FEV1 was recorded with a daily calibrated dry
spirometer (Schiller SP-100; Schiller, Vaar, Switzer-
land). Dyspnoea was assessed by the modified Borg
score.9 Patients were shown a large written printed
explanation of the score ratings and were asked to
rate their shortness of breath on a scale of 0–10,
with 0¼ nothing and 10¼maximal.
Statistical analysis
The primary endpoint of this post-hoc analysis was
the time from inhalation of the study drug (i.e. end
of provocation test, T ¼ 0) to sense the first
improvement of Borg score. This time point is
considered to be the onset of relief of dyspnoea. A
secondary parameter was the time needed to
return to the pre-provocation Borg score. In those
cases where the Borg score did not return to the
pre-methacholine values, the recovery time was
arbitrarily set at 75min. Other parameters ana-
lysed were FEV1 at the time of onset of relief of
dyspnoea (as percentage change from the T ¼ 0
value), and the FEV1 at the time when Borg score
returned to pre-methacholine value (as percentage
change from the pre-methacholine baseline). Data
on recovery times are presented as geometric
means (Gmean) because of the non-normal dis-
tribution.
The Wilcoxon Signed Rank test is used to
compare treatments. A P-valuep0.05 is considered
statistically significant.
Results
Twenty-one patients were enrolled. Two patients
were withdrawn because of unstable asthma; one
patient did not attend agreed visits while another
failed to achieve a fall of at least 30% after
methacholine challenge. The remaining 17 patients
completed the four test days. The demographic
data of these patients are shown in Table 1.
Baseline conditions prior to inhalation of study
medication, i.e. FEV1, Borg scores, and PC20 values
were comparable on all study days, except for the
methacholine-induced fall in FEV1, which was
largest before the administration of formoterol
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(Table 2). The methacholine-induced increase in
Borg score and the decrease in FEV1, faded away
gradually in all treatment arms (Fig. 1), though not
complete within 60min after placebo.
Time to onset of first improvement in Borg
score
Within 2min after inhalation of formoterol and
salbutamol, an improvement in Borg score was
reported. Gmean time (range) values of the first
sensed improvement were 1.5 (1–40)min for for-
moterol, 1.7 (1–10)min for salbutamol, 4.5 (1–
30)min for salmeterol and 3.4 (1–40)min for
placebo. The onset of effect of formoterol and
salbutamol both differed significantly from placebo
(both Pp0:05) and salmeterol (both Pp0:01;
Fig. 2). Salmeterol did not differ from placebo.
At the moment of the first sensed improvement,
FEV1 values had improved as well, but were still
below pre-methacholine baseline. FEV1 had im-
proved with mean (standard deviation (SD)) 15.9
(11.9)%, 18.4 (10.24)%, 13.9 (12.4)% and 10.6 (7.6)%
after formoterol, salbutamol, salmeterol, and
placebo, respectively. The differences between
the four treatments were not significant.
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Table 1 Patients demographics.
Male, n (%) 5 (29)
Mean age, years (range) 30 (18–41)
Mean FEV1, L (range) 3.29 (2.09–5.17)
Mean FEV1, % predicted
normal (range)
96 (73–122)
Gmean PC20, mgml
1
(range)
0.70 (0.06–5.00)
Inhaled steroid use, n (%) 15 (88)
b2-agonist reliever use, n
(%)
17 (100)
Gmean¼ geometric mean; PC20 provocative concentra-
tion of methacholine causing a forced expiratory flow in
1 s (FEV1) to fall by 20%.
Table 2 Baseline conditions on each study day (n¼ 17).
FEV1 (l) % Decrease in FEV1
from pre-
methacholine
Borg score after
methacholine
provocation (units)
PC20 (mgml
1)
Formoterol 3.370.8 45.4711.7 3 (1–9) 1.1 (0.4–7.0)
Salbutamol 3.370.8 41.278.8 2 (0.5–8) 0.8 (0.3–4.3)
Salmeterol 3.270.8 38.970.8 2 (0.5–9) 0.9 (0.3–8.3)
Placebo 3.270.9 44.7711.2 3 (0.5–9) 1.0 (0.3–7.2)
Data are mean7SD except Borg score: median (range) and PC20: Gmean (range). PC20 provocative concentration of
methacholine causing a forced expiratory flow in 1 s (FEV1) to fall by 20%.
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Figure 1 Borg score (A) and FEV1 (as percentage change from baseline); (B) during the first 60min following inhalation
of study medication after methacholine-induced bronchoconstriction.
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Time to return to baseline Borg score
After placebo treatment, it lasted approximately
half an hour before the effects of methacholine on
dyspnoea were completely gone, after active
treatments the recovery went faster. The Gmean
(range) values for the recovery time were 13.8 (1–
75)min for formoterol, 13.4 (1–60)min for salbu-
tamol, 18.0 (1–75)min for salmeterol, and 33.6 (1–
75)min for placebo. The values were significantly
different between placebo and all active treat-
ments (Pp0:001), yet not between active treat-
ments (Fig. 3).
The Borg score did not return to pre-methacho-
line values in 3 of 17 cases after inhalation of
formoterol, 0/17 after salbutamol, 1/17 after
salmeterol and 7/17 cases after inhalation of
placebo. At the moment that the Borg score had
returned to its baseline value, mean FEV1 values
were still lower than at the beginning of the test.
The remaining % falls in FEV1 on the formoterol,
salbutamol, salmeterol, and placebo test days were
10.1 (7.6)%, 10.5 (12.5)%, 10.8 (11.4)%, and 15.8
(15.1)%, respectively below pre-methacholine
baseline values.
Discussion
This post-hoc analysis shows that the onset of relief
of dyspnoea, measured by the modified Borg score,
is significantly faster achieved with inhalation of
the rapidly acting b2-receptor agonists formoterol
and salbutamol than with salmeterol or placebo.
Thus, the rapid bronchodilating effects of formo-
terol and salbutamol are perceived by patients as
well.
After inhalation of both placebo and salmeterol,
the first moment that the patients sense an
improvement of dyspnoea occurs at 5min. Thus,
it takes 4–5min before the methacholine starts to
fade away. The onset of dyspnoea relief with
salmeterol does not differ significantly from that
after placebo and is therefore too slow to be
accurately perceived by patients in the present
model. The complete recovery of methacholine-
induced dyspnoea with salmeterol is detected after
a mean of 18min after inhalation, not significantly
slower than with formoterol and salbutamol, but
significantly faster than with placebo. We conclude
that rapidly acting bronchodilators formoterol and
salbutamol not only provide rapid bronchodilation7
but a rapidly sensed onset of relief of dyspnoea
as well.
Different methods have been applied to assess
the perception of dyspnoea, for instance the Visual
analogue scale10,11 and modified Borg score.9,12,13
We have used the modified Borg score to determine
the perception of dyspnoea, because Borg scale
scores have been found to be better reproducible
than outcomes of the Visual Analogue Scale.9
Moreover, Borg scores are easy to measure, easily
understood, and mimic closely real-life situations,
when people use semantics to describe the percep-
tion of dyspnoea. The magnitude of modified Borg
scores (between 0 and 10) gives an estimate of the
severity of perceived dyspnoea14 and in analogy of
the visual analogue score represents the individu-
ally assessed inconvenience of asthma symptoms
during provocation tests.11 For this reason, we did
not present the absolute levels of Borg scores in
calculating the onset of the perception of improve-
ment of dyspnoea, but primarily the individually
assessed time points when the Borg scores im-
proved in each individual patient. The latter
represents more accurately the individual patient’s
ability to subjectively perceive clinically relevant
effects, in line with objective changes in lung
function.11
After the first timepoint when the Borg score had
returned to baseline values, some bronchoconstric-
tion remained. This is not an unexpected finding as
in earlier studies using methacholine-induced
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Figure 3 Gmean with 95% confidence interval for the
recovery time of Borg score to return to baseline value
following inhalation of study medication after methacho-
line-induced bronchoconstriction. Pp0:001 versus pla-
cebo.
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Figure 2 Gmean and 95% confidence interval for the
time to the first sensed improvement of Borg score
following inhalation of study medication after methacho-
line-induced bronchoconstriction. Pp0:05 versus place-
bo; Pp0:01 versus salmeterol.
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bronchoconstriction, approximately a 10% fall in
FEV1 is the minimal difference which is perceived in
patients with asthma12
When methacholine is applied to induce bronch-
oconstriction, the induced bronchoconstriction is
solely due to airway smooth muscle cells contrac-
tion. Therefore, we believe that methacholine-
induced bronchoconstriction is a proper model to
investigate the bronchodilating effects of b2-ago-
nists by reversing the airway smooth muscle
contraction that accompanies an acute sponta-
neous asthma attack.
In summary, a single inhalation of formoterol and
salbutamol induce a relief of dyspnoea within
2min, in methacholine-induced bronchoconstric-
tion as a model to induce dyspnoea in patients with
asthma. The onset of dyspnoea relief provided by
salmeterol could not be determined in this model
since the spontaneous recovery of dyspnoea oc-
curred at the same time as with placebo. Notwith-
standing the observed faster onset of dyspnoea
relief with formoterol and salbutamol, complete
recovery of induced dyspnoea was always obtained
more rapidly with all three b2-agonists in compar-
ison with placebo.
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